In the mid-range of estimates, anywhere from 56% to 62% of Americans currently being treated for depression could be eligible to try psilocybin. The number could even grow higher if people currently untreated for their depression decide they would like to try psilocybin, the investigators noted. Original Article (Newsweek):Over 5 million Americans could benefit if psilocybin…
Psilocybin was supplied by Usona Institute… (Open Science and Praxis Signatories) here we tracked individual-specific brain changes with longitudinal precision functional mapping (roughly 18 magnetic resonance imaging visits per participant). Healthy adults were tracked before, during and for 3 weeks after high-dose psilocybin (25 mg) and methylphenidate (40 mg), and brought back for an additional psilocybin dose 6–12 months…
…if someone is desperate and suicidal, of course they should be able to try psychedelics, as quickly and safely as possible. The healthcare system is broken, the FDA approval system is slow and very expensive…and people can sometimes heal themselves outside of the medical system. Clusterbusters is a really interesting example of a peer support group which…
…it appears as though the owners of psilocybin shops have no plans to shut down for good. “This is like some kind of terrible drug war anachronism from some other era that shouldn’t even be on the books and we’re hopefully going to change that,” FunGuyz lawyer Paul Lewin. According to the former Ontario Provincial…
While psychedelics are sometimes portrayed in media as causing intense paranoia, particularly in a recreational setting, the study authors said psilocybin “was not associated with risk of paranoia and transient thought disorder.” The researchers identified five other reported adverse effects among certain patients in the clinical trials: headache, nausea, anxiety, dizziness and elevated blood pressure.…
…an LSD analog, L S D (Lysergide D-Tartrate) was given “breakthrough therapy” designation by the FDA for treating anxiety. …this analog… a tartrate salt form… called MM-120. A single oral administration (100 µg) of this psychelic analog, MM120, maintained a clinically and statistically significant reduction in symptoms compared to placebo at 12 weeks — with…
The current context into which psychedelics emerge finds its backdrop in the late 1960s and early 1970s, a defining era in American history. This period was marked by President Nixon’s War on Drugs and a significant economic shift as the U.S. officially departed from the gold standard in 1971. …links these two historical decisions, “Classifying…
“Our study explored whether those who engaged in recreational psilocybin use also had lesser psychological distress,” he said. “It also explored whether the effect of psilocybin in reducing distress appeared to differ according to the level of childhood adversity.” In short, the answer is yes to both outcomes. To measure distress, researchers asked participants to…
The Psychedelic Preparedness Scale (PPS)… represents a significant contribution to the field of psychedelic research. The scale, validated through a comprehensive three-study approach, assesses various dimensions of preparedness for psychedelic experiences. The findings suggest that individuals who score higher on the PPS tend to have more positive acute and long-term outcomes associated with psychedelic use.…
…researchers at the University of Chicago have discovered that low doses of lysergic acid diethylamide (LSD), a psychedelic drug, may have potential antidepressant effects in individuals showing mild to moderate depressive symptoms… the findings have been published in the journal Neuropsychopharmacology. “There has been a great deal of public interest in ‘microdosing,’ or the idea…
Recent Comments